Sequana Medical 2022 Investor Presentation: Diuretic-Resistant Fluid Overload

Sequana Medical presents its technology platforms for treating diuretic-resistant fluid overload, including the alfapump® system under clinical investigation for refractory ascites and DSR® therapy in development. The presentation outlines the company's innovation approach and clinical programs as of January 2022.